TY - JOUR
T1 - Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I
T2 - Relevance to dopamine pathology in schizophrenia
AU - Brenner-Lavie, Hanit
AU - Klein, Ehud
AU - Zuk, Rosa
AU - Gazawi, Haifa
AU - Ljubuncic, Predrage
AU - Ben-Shachar, Dorit
N1 - Funding Information:
This work was supported in part by a grant from Chief Scientist Israel Ministry of Health, and the Center for Absorption in Science, Ministry of Immigrant Absorption, State of Israel.
PY - 2008/2
Y1 - 2008/2
N2 - Deleterious effects of dopamine (DA) involving mitochondrial dysfunction have an important role in DA-associated neuronal disorders, including schizophrenia and Parkinson's disease. DA detrimental effects have been attributed to its ability to be auto-oxidized to toxic reactive oxygen species. Since, unlike Parkinson's disease, schizophrenia does not involve neurodegenerative processes, we suggest a novel mechanism by which DA impairs mitochondrial function without affecting cell viability. DA significantly dissipated mitochondrial membrane potential (Δψm) in SH-SY5Y cells. Bypassing complex I prevented the DA-induced depolarization. Moreover, DA inhibited complex I but not complex II activity in disrupted mitochondria, suggesting complex I participation in DA-induced mitochondrial dysfunction. We further demonstrated that intact mitochondria can accumulate DA in a saturated manner, with an apparent Km = 122.1 ± 28.6 nM and Vmax = 1.41 ± 0.15 pmol/mg protein/min, thereby enabling the interaction between DA and complex I. DA accumulation was an energy and Na+-dependent process. The pharmacological profile of mitochondrial DA uptake differed from that of other characterized DA transporters. Finally, relevance to schizophrenia is demonstrated by an abnormal interaction between DA and complex I in schizophrenic patients. These results suggest a non-lethal interaction between DA and mitochondria possibly via complex I, which can better explain DA-related pathological processes observed in non-degenerative disorders, such as schizophrenia.
AB - Deleterious effects of dopamine (DA) involving mitochondrial dysfunction have an important role in DA-associated neuronal disorders, including schizophrenia and Parkinson's disease. DA detrimental effects have been attributed to its ability to be auto-oxidized to toxic reactive oxygen species. Since, unlike Parkinson's disease, schizophrenia does not involve neurodegenerative processes, we suggest a novel mechanism by which DA impairs mitochondrial function without affecting cell viability. DA significantly dissipated mitochondrial membrane potential (Δψm) in SH-SY5Y cells. Bypassing complex I prevented the DA-induced depolarization. Moreover, DA inhibited complex I but not complex II activity in disrupted mitochondria, suggesting complex I participation in DA-induced mitochondrial dysfunction. We further demonstrated that intact mitochondria can accumulate DA in a saturated manner, with an apparent Km = 122.1 ± 28.6 nM and Vmax = 1.41 ± 0.15 pmol/mg protein/min, thereby enabling the interaction between DA and complex I. DA accumulation was an energy and Na+-dependent process. The pharmacological profile of mitochondrial DA uptake differed from that of other characterized DA transporters. Finally, relevance to schizophrenia is demonstrated by an abnormal interaction between DA and complex I in schizophrenic patients. These results suggest a non-lethal interaction between DA and mitochondria possibly via complex I, which can better explain DA-related pathological processes observed in non-degenerative disorders, such as schizophrenia.
KW - Complex I
KW - Dopamine
KW - Mitochondria
KW - Mitochondrial dopamine uptake
KW - Mitochondrial membrane potential
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=38549125376&partnerID=8YFLogxK
U2 - 10.1016/j.bbabio.2007.10.006
DO - 10.1016/j.bbabio.2007.10.006
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:38549125376
SN - 0005-2728
VL - 1777
SP - 173
EP - 185
JO - Biochimica et Biophysica Acta - Bioenergetics
JF - Biochimica et Biophysica Acta - Bioenergetics
IS - 2
ER -